Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group

Resistance of advanced hormone‐dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves the progression‐free rate compared to Anastrozole alo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mourksi, Nour‐El‐Houda, Dalban, Cécile, Colombe‐Vermorel, Amélie, Odeyer, Laetitia, Simioni, Valentin, Frenel, Jean‐Sébastien, Fabbro, Michel, Bazan, Fernando, Abadie‐Lacourtoisie, Sophie, Coquan, Elodie, Martinez, Séverine, Garin, Gwenaelle, Tabone‐Eglinger, Séverine, Treilleux, Isabelle, Chabaud, Sylvie, Pérol, David, Ray‐Coquard, Isabelle, Heudel, Pierre‐Etienne, Diaz, Jean‐Jacques, Marcel, Virginie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812831/
https://www.ncbi.nlm.nih.gov/pubmed/36370117
http://dx.doi.org/10.1002/1878-0261.13340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812831/
https://www.ncbi.nlm.nih.gov/pubmed/36370117
http://dx.doi.org/10.1002/1878-0261.13340

Ejemplares similares